DOCSLIB.ORG

Identification of Potentially Inappropriate Medications with Risk

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Potentially Inappropriate Medications with Risk Journal name: Clinical Interventions in Aging Article Designation: Original Research Year: 2019 Volume: 14 Clinical Interventions in Aging Dovepress Running head verso: Aguiar et al Running head recto: Aguiar et al open access to scientific and medical research DOI: 192252 Open Access Full Text Article ORIGINAL RESEARCH Identification of potentially inappropriate medications with risk of major adverse cardiac and cerebrovascular events among elderly patients in ambulatory setting and long-term care facilities This article was published in the following Dove Medical Press journal: Clinical Interventions in Aging João Pedro Aguiar1 Purpose: Cardiovascular diseases (CVDs) are extremely common among the elderly, but Luís Heitor Costa2 information on the use of potentially inappropriate medications (PIMs) with cardiovascular Filipa Alves da Costa3,4 risk is scarce. We aimed to determine the prevalence of PIMs with risk of cardiac and cere- Hubert GM Leufkens5 brovascular adverse events (CCVAEs), including major adverse cardiac and cerebrovascular Ana Paula Martins1 events (MACCE). Patients and methods: A cross-sectional study was performed using a convenience sample 1Research Institute for Medicines (iMED.ULisboa), Faculdade de from four long-term care facilities and one community pharmacy in Portugal. Patients were For personal use only. Farmácia, Universidade de Lisboa, included if they were aged 65 or older and presented at least one type of medication in their 2 Lisboa, Portugal; Serviço de medical and pharmacotherapeutic records from 2015 until December 2017. The main outcome Medicina Interna, Centro Hospitalar Psiquiátrico de Lisboa (CHPL), Lisboa, was defined as the presence of PIMs with risk of MACCE and was assessed by applying a Portugal; 3Centro de Investigação PIM-MACCE list that was developed from a previous study. All medications included in this Interdisciplinar Egas Moniz (CiiEM), list were assessed for their availability in Portugal. Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal; 4Faculdade Results: A total of 680 patients were included. Of those, 428 (63%) were female with a mean de Farmácia, Universidade de Lisboa, age of 78.4±8.1 years. Four-hundred and four (59.4%) patients were taking medications asso- Lisboa, Portugal; 5Division of Pharmacoepidemiology and Clinical ciated with CCVAEs risk (mean =1.7±1.0 drugs/patient), including 264 patients (38.8%) who Pharmacology, Utrecht Institute for used drugs with MACCE risk (mean =1.4±0.8 drugs/patient). Fifty percent of patients with a Pharmaceutical Sciences, Utrecht previous history of CVD (n=521) were taking PIMs with risk of CCVAEs, including 30.0% University, Utrecht, the Netherlands with risk of MACCE. Our findings show that 50% of patients with previous history of CVD were taking Clinical Interventions in Aging downloaded from https://www.dovepress.com/ by 195.23.63.110 on 13-Nov-2019 Conclusion: drugs with risk of CCAVEs and 30% with risk of MACCE. More tailored tools for the manage- ment of drug therapy in elderly patients with CVD are of major importance in clinical practice. Keywords: patient safety, therapeutic uses, outcome process assessment (health care), cardio- vascular risk, NSAIDs, antipsychotics Introduction The elderly are usually fragile and more susceptible to drug-related problems as a result of multimorbidity, polypharmacy, and physiological changes that affect the Correspondence: João Pedro Aguiar 1 Research Institute for Medicines (iMED. pharmacokinetics and pharmacodynamics of drugs. Therefore, this population is more ULisboa), Faculdade de Farmácia prone to using medications that can be considered inappropriate. da Universidade de Lisboa, Avenida A potentially inappropriate medication (PIM) is any medication used by a patient Professor Gama Pinto, 1649-003 Lisboa, Portugal that could introduce a significant risk of an adverse drug reaction (ADR), in particular Tel +351 96 910 4137 when there is an equally or more effective alternative with lower risk available. Fax +351 21 794 6470 Email [email protected] In the elderly, ADRs can sometimes be difficult to recognize as they often present submit your manuscript | www.dovepress.com Clinical Interventions in Aging 2019:14 535–547 535 Dovepress © 2019 Aguiar et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you http://dx.doi.org/10.2147/CIA.S192252 hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Powered by TCPDF (www.tcpdf.org) 1 / 1 Aguiar et al Dovepress with unspecific symptoms (eg, falls, fatigue, and orthostatic of PIMs described addressing their association with the risk hypotension). ADRs are observed 2–3 times more often in the of cardiovascular adverse events.20 Some pharmacothera- elderly and account for 5%–17% of all hospital admissions.2 peutic groups have been established to be associated with A systematic review has found a mean prevalence of ADRs cardiovascular events such as nonsteroidal anti-inflammatory in the elderly of 11% (95% CI: 5.1%–16.8%) and a preva- drugs (NSAIDs), antipsychotics, selective calcium chan- lence of ADRs leading to hospitalization of 10% (95% CI: nel blockers, and dopaminergic agents. Unfortunately, the 7.2–12.8). These authors have also shown that increased prevalence of those PIMs in elderly patients is still unknown. comorbid complexity and increased number of medications The primary objective of this study was to assess the were significantly associated with an increased risk of ADRs.3 prevalence of PIMs with risk of MACCE in the elderly. We It is estimated that 30%–60% could be prevented.2 A recent then specifically aimed to study the prevalence of PIMs with study has shown that 45.1% (95% CI: 33.1%–57.2%) of the risk of cardiac and cerebrovascular adverse events (CCVAEs) ADRs leading to hospitalization were preventable.4 In the and to study the presence of these PIMs in patients with USA and Canada, the prevalence ranged between 14% and previous history of CVD. 37.0%;5 in Europe, the prevalence ranged between 23% and 43%.6 Differences found between both continents could be Materials and methods explained by different drug markets, different prescribing Study design patterns, and most importantly, by the tool used to measure A descriptive cross-sectional study was conducted, where a prevalence.7 convenience sample (based on geographic criteria) of citizens Several tools have been developed to guide prescrib- living in long-term care facilities (LTCFs) in the region of ing, to maximize the efficacy and safety of therapy, and to Lisboa e Vale do Tejo and the region of Alentejo and inde- minimize the consequences of using PIMs, including costs, pendently in their own home (ambulatory) in the region of hospitalizations, and mortality.8 The Beers criteria (Mark Lisboa e Vale do Tejo, Portugal were invited to participate. Beers, MD) was the first tool, developed in 1991, and last Citizens’ information (including drug use) was collected For personal use only. updated in 2019 by the American Geriatric Society.9,10 Since from two LTCFs in the region of Lisboa e Vale do Tejo and then, a considerable number of tools have been developed, two LTCFs in the other region of Alentejo. While, for indi- describing not only PIMs, but also drug–drug and drug– viduals who live independently in their own home, citizens’ disease interactions.3 Most of these tools are based on explicit information was collected from their community pharmacy. criteria, ie, are normally more drug- or disease-oriented and are developed based on literature review, expert opinions, Population and sample and consensus techniques.3 The study population (n=904) consisted of 224 residents Cardiovascular diseases ([CVDs] which also include and 680 patients from the community pharmacy and the cerebrovascular diseases) such as hypertension, coronary LTCF, respectively. In the LTCF, residents were eligible heart disease, congestive heart failure, stroke, and atrial fibril- if they were aged 65 or older and living in the facility until Clinical Interventions in Aging downloaded from https://www.dovepress.com/ by 195.23.63.110 on 13-Nov-2019 lation are prevalent among the elderly.11 They represent one 2017. In the community pharmacy, the study population was of the leading causes of death worldwide, with 17.7 million calculated based on the minimum legal number of inhabit- deaths registered in 2015 (31.0% of all-cause mortality).12,13 ants per pharmacy (3,500 inhabitants) and on the percentage In Europe, 3.9 million people (45.0% of all-cause mortality) of elderly living in the district of Cascais in 2016 (19.6%). have died from CVDs in 2016.13 Moreover, individuals were included if they were aged 65 Few studies have identified PIMs in patients with CVD. or older and had their medication history available in the A study conducted in a cardiology service showed that pharmacy database in 2017. We excluded patients if their 20% of hospitalized patients were previously exposed to a records were out of date, ie, if there were no sales in 2017. PIM in the ambulatory setting.14 However, information on PIMs associated with risk of cardiovascular adverse events, Outcomes’ definition and measurement especially with major adverse cardiac and cerebrovascular Our previous study focused on a systematic review of events (MACCE) for elderly is still scarce. Some of these 24 PIM-lists, where PIMs associated with CCVAEs and medications can increase the risk of cardiovascular events MACCE were identified (Table S1 shows the full list of those or even exacerbate underlying conditions.
Load more

Recommended publications
  • Vasodilators for Primary Raynaud's Phenomenon
    Vasodilators for primary Raynaud's phenomenon Author Su, KYC, Sharma, M, Kim, HJ, Kaganov, E, Hughes, I, Abdeen, MH, Ng, JHK Published 2021 Journal Title Cochrane Database of Systematic Reviews Version Version of Record (VoR) DOI https://doi.org/10.1002/14651858.CD006687.pub4 Copyright Statement © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. This review is published as a Cochrane Review in the Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687.. Cochrane Reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the Review. Downloaded from http://hdl.handle.net/10072/405317 Griffith Research Online https://research-repository.griffith.edu.au Cochrane Library Cochrane Database of Systematic Reviews Vasodilators for primary Raynaud's phenomenon (Review) Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JHK Su KYC, Sharma M, Kim HJ, Kaganov E, Hughes I, Abdeen MH, Ng JH. Vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD006687. DOI: 10.1002/14651858.CD006687.pub4. www.cochranelibrary.com Vasodilators for primary Raynaud's phenomenon (Review) Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane Trusted evidence. Informed decisions. Library Better health. Cochrane Database of Systematic Reviews T A B L E O F C O N T E N T S HEADER........................................................................................................................................................................................................
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation
    www.sciencemag.org/cgi/content/full/327/5963/348/DC1 Supporting Online Material for Zebrafish Behavioral Profiling Links Drugs to Biological Targets and Rest/Wake Regulation Jason Rihel,* David A. Prober, Anthony Arvanites, Kelvin Lam, Steven Zimmerman, Sumin Jang, Stephen J. Haggarty, David Kokel, Lee L. Rubin, Randall T. Peterson, Alexander F. Schier* *To whom correspondence should be addressed. E-mail: [email protected] (A.F.S.); [email protected] (J.R.) Published 15 January 2010, Science 327, 348 (2010) DOI: 10.1126/science.1183090 This PDF file includes: Materials and Methods SOM Text Figs. S1 to S18 Table S1 References Supporting Online Material Table of Contents Materials and Methods, pages 2-4 Supplemental Text 1-7, pages 5-10 Text 1. Psychotropic Drug Discovery, page 5 Text 2. Dose, pages 5-6 Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors, page 6 Text 4. Polypharmacology, pages 6-7 Text 5. Pharmacological Conservation, pages 7-9 Text 6. Non-overlapping Regulation of Rest/Wake States, page 9 Text 7. High Throughput Behavioral Screening in Practice, page 10 Supplemental Figure Legends, pages 11-14 Figure S1. Expanded hierarchical clustering analysis, pages 15-18 Figure S2. Hierarchical and k-means clustering yield similar cluster architectures, page 19 Figure S3. Expanded k-means clustergram, pages 20-23 Figure S4. Behavioral fingerprints are stable across a range of doses, page 24 Figure S5. Compounds that share biological targets have highly correlated behavioral fingerprints, page 25 Figure S6. Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles, page 26 Figure S7.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Neuroenhancement in Healthy Adults, Part I: Pharmaceutical
    l Rese ca arc ni h li & C f B o i o l e Journal of a t h n Fond et al., J Clinic Res Bioeth 2015, 6:2 r i c u s o J DOI: 10.4172/2155-9627.1000213 ISSN: 2155-9627 Clinical Research & Bioethics Review Article Open Access Neuroenhancement in Healthy Adults, Part I: Pharmaceutical Cognitive Enhancement: A Systematic Review Fond G1,2*, Micoulaud-Franchi JA3, Macgregor A2, Richieri R3,4, Miot S5,6, Lopez R2, Abbar M7, Lancon C3 and Repantis D8 1Université Paris Est-Créteil, Psychiatry and Addiction Pole University Hospitals Henri Mondor, Inserm U955, Eq 15 Psychiatric Genetics, DHU Pe-psy, FondaMental Foundation, Scientific Cooperation Foundation Mental Health, National Network of Schizophrenia Expert Centers, F-94000, France 2Inserm 1061, University Psychiatry Service, University of Montpellier 1, CHU Montpellier F-34000, France 3POLE Academic Psychiatry, CHU Sainte-Marguerite, F-13274 Marseille, Cedex 09, France 4 Public Health Laboratory, Faculty of Medicine, EA 3279, F-13385 Marseille, Cedex 05, France 5Inserm U1061, Idiopathic Hypersomnia Narcolepsy National Reference Centre, Unit of sleep disorders, University of Montpellier 1, CHU Montpellier F-34000, Paris, France 6Inserm U952, CNRS UMR 7224, Pierre and Marie Curie University, F-75000, Paris, France 7CHU Carémeau, University of Nîmes, Nîmes, F-31000, France 8Department of Psychiatry, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Eschenallee 3, 14050 Berlin, Germany *Corresponding author: Dr. Guillaume Fond, Pole de Psychiatrie, Hôpital A. Chenevier, 40 rue de Mesly, Créteil F-94010, France, Tel: (33)178682372; Fax: (33)178682381; E-mail: [email protected] Received date: January 06, 2015, Accepted date: February 23, 2015, Published date: February 28, 2015 Copyright: © 2015 Fond G, et al.
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • Synthetic Repurposing of Drugs in Hypertension: a Datamining Method Based on Association Rules and a Novel Discrete Algorithm
    Synthetic Repurposing of Drugs in Hypertension: a Datamining Method Based on Association Rules and a Novel Discrete Algorithm Yosef Masoudi-Sobhanzadeh University of Tehran Ali Masoudi-Nejad ( [email protected] ) https://orcid.org/0000-0003-0659-5183 Methodology article Keywords: Data mining, Drug repurposing, Hypertension, Optimization algorithm, Synthetic repurposing Posted Date: May 11th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-25124/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published on July 16th, 2020. See the published version at https://doi.org/10.1186/s12859-020-03644-w. Synthetic Repurposing of Drugs in Hypertension: a Datamining Method Based on Association Rules and a Novel Discrete Algorithm Yosef Masoudi-Sobhanzadeh1,a, Ali Masoudi-Nejad1,* 1. Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran a [email protected] *Corresponding Author Ali Masoudi-Nejad, Ph.D, Laboratory of Systems Biology and Bioinformatics (LBB) Institute of Biochemistry and Biophysics University of Tehran, Tehran, Iran. E-mail: [email protected] WWW: http://LBB.ut.ac.ir 1 Abstract Background: Drug repurposing aims to detect the new benefits of the existing drugs and to reduce the spent time and cost of the drug development projects. Although synthetic repurposing of drugs may be more useful than single repurposing in terms of reducing toxicity and enhancing efficacy, the researchers have not taken it into account. To address the issue, a novel datamining method is introduced and applied to the repositioning of drugs in hypertension (HT), which is a serious medical condition and therefore needs to be dealt with effectively through making some improved treatment plans to help cure it.
    [Show full text]
  • Anticholinergic Burden Quantified by Anticholinergic Risk Scales And
    Salahudeen et al. BMC Geriatrics (2015) 15:31 DOI 10.1186/s12877-015-0029-9 RESEARCH ARTICLE Open Access Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review Mohammed Saji Salahudeen, Stephen B Duffull and Prasad S Nishtala* Abstract Background: The cumulative effect of taking multiple medicines with anticholinergic properties termed as anticholinergic burden can adversely impact cognition, physical function and increase the risk of mortality. Expert opinion derived risk scales are routinely used in research and clinical practice to quantify anticholinergic burden. These scales rank the anticholinergic activity of medicines into four categories, ranging from no anticholinergic activity (= 0) to definite/high anticholinergic activity (= 3). The aim of this systematic review was to compare anticholinergic burden quantified by the anticholinergic risk scales and evaluate associations with adverse outcomes in older people. Methods: We conducted a literature search in Ovid MEDLINE, EMBASE and PsycINFO from 1984-2014 to identify expert opinion derived anticholinergic risk scales. In addition to this, a citation analysis was performed in Web of Science and Google Scholar to track prospective citing of references of selected articles for assessment of individual scales for adverse anticholinergic outcomes. The primary outcomes of interest were functional and cognitive outcomes associated with anticholinergic burden in older people. The critical appraisals of the included studies were performed by two independent reviewers and the data were extracted onto standardised forms. Results: The primary electronic literature search identified a total of 1250 records in the 3 different databases. On the basis of full-text analysis, we identified 7 expert-based anticholinergic rating scales that met the inclusion criteria.
    [Show full text]